A study published in JAMA Oncology found that boys and young men who received the human papillomavirus (HPV) vaccine had a 46% lower risk of developing HPV-related cancers compared to unvaccinated individuals.
Key Study Findings
- The analysis included over 615,000 vaccinated males and 2 million unvaccinated males, all aged 9 to 26.
- After statistical adjustment, the vaccinated group showed a 46% reduction in risk for HPV-related cancers.
- Benefits were consistent across age groups:
- 42% lower risk for those vaccinated between ages 9 and 14.
- 50% lower risk for those vaccinated between ages 15 and 26.
Background on HPV
- HPV is a common sexually transmitted infection; nearly all sexually active people are exposed at some point.
- High-risk HPV types can cause cancers of the cervix, vagina, vulva, penis, anus, and oropharynx.
- The vaccine was initially emphasized for females due to the burden of cervical cancer, but recommendations now include males.
Current Recommendations
- The CDC recommends routine vaccination at ages 11–12, with a range of 9–26 years.
- Catch-up vaccination is recommended through age 26.
- For adults aged 27–45, shared clinical decision-making is advised.
Expert Statement
"The vaccine is about preventing cancer and has a well-established safety profile."
— Dr. Leana Wen